NRC — Preclinical in vivo facility
- Open continuously
Overview
Fee-for-service facility that enables clients to validate their biologics and vaccine design approaches and obtain a clear picture of the preclinical safety and efficacy of their products.
At a glance
Funding available
- Increase performance through digital transformation
- Develop a new product or service
- Conduct research and development activities
- No Condition
- Open continuously
Eligible candidates
- Professional, scientific and technical services
- Health care and social assistance
- Canada
- For-profit business
- All revenue ranges
- All organization sizes
- Startups
Next steps
Activities funded
This grant supports projects and activities centered on the evaluation and preclinical characterization of biologics and vaccines. These initiatives are designed to produce critical data for preparing Investigational New Drug (IND) applications.
- Validation of therapeutic targets and biomarkers for cancer, infectious, inflammatory, and central nervous system (CNS) diseases.
- Evaluation of biomarker/target expression, pharmacokinetics, pharmacodynamics, and brain penetration of biologics in cell, tissue, and animal models.
- Vaccine uptake and distribution studies; evaluation of formulations for the induction of immune responses.
- Efficacy studies in challenge models for infectious disease and cancer vaccines.
- Animal model development for preclinical studies.
- Development of novel molecular imaging tools, including nanocarriers and contrast agents.
- Creation of methodologies for cell, tissue, and whole-body imaging in small animals.
Eligibility
Who is eligible?
This grant is open to biotechnology and biopharmaceutical companies seeking to validate their biologics and vaccines through preclinical studies, leveraging NRC's specialized expertise and advanced facilities. Eligible applicants include organizations involved in therapeutic targets and biomarker validation for various diseases, biologics evaluation, and vaccine development.Eligible expenses
The NRC's grant supports projects aimed at advancing the evaluation and development of biologics and vaccines, leveraging extensive expertise and state-of-the-art facilities. Eligible projects span various activities crucial for the preclinical safety and efficacy assessment of therapeutic interventions.
- Validation of therapeutic targets and biomarkers for various diseases including cancer, infectious, inflammatory, and CNS diseases.
- Evaluation of biomarker/target expression, pharmacokinetics, and pharmacodynamics.
- Studies on vaccine uptake, distribution, and immune response validation.
- Efficacy studies in challenge models for both infectious disease and cancer vaccines.
- Development of animal models for preclinical studies.
- Creation of novel molecular imaging tools and methodologies for small animal imaging.
- Comprehensive imaging support using advanced optical and hyperspectral systems.
Eligible geographic areas
The funding information provided does not specify eligible geographical areas for companies applying for this grant. Therefore, the eligible locations cannot be determined from the given context.
Additional information
- The NRC's preclinical in vivo facility provides expertise in cancer, infectious, inflammatory, and CNS diseases. - Evaluation includes biomarker/target expression, pharmacokinetics, pharmacodynamics, and brain penetration of biologics in various models. - Vaccine studies cover uptake, distribution, immune response induction, and efficacy in challenge models. - Animal model development and customization are available. - The facility offers state-of-the-art imaging tools, from optical to microCT and mass spectrometry. - Experienced in working with various animal species and specialized surgical procedures. - Behavioral testing capabilities include maze tests. - Access to a range of imaging systems and microscopy platforms for detailed analysis. - The team at the facility has over 25 years of experience and can help with IND applications. - Good Animal Practice certification and ethical review processes are in place. - The location of the facility is in Ottawa, Ontario, Canada.
Documents and links
Frequently Asked Questions about the NRC — Preclinical in vivo facility Program
What is the NRC — Preclinical in vivo facility?
Who is eligible for the NRC — Preclinical in vivo facility program?
What expenses are eligible under NRC — Preclinical in vivo facility?
Who can I contact for more information about the NRC — Preclinical in vivo facility?
Where is the NRC — Preclinical in vivo facility available?
Is the NRC — Preclinical in vivo facility a grant, loan, or tax credit?
Who are the financial supporters of the NRC — Preclinical in vivo facility?
More programs like this
- Industrial Research Assistance Program (IRAP) – AI Assist$750,000-$10,500,000100%
Mitacs Accelerate$7,500-$15,000- Mitacs — Elevate$30,000-$120,00050%
Enhanced Road Safety Transfer Payment Program (ERSTPP)Max $10,000,00075%
